JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients
Open Access
- 12 January 2006
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 20 (3) , 534-535
- https://doi.org/10.1038/sj.leu.2404086
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemiaBlood, 2005
- The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patientsBlood, 2005
- JAK2V617F mutation in essential thrombocythaemia: clinical associations and long‐term prognostic relevanceBritish Journal of Haematology, 2005
- Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersBlood, 2005
- The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromesBlood, 2005
- Identification of an Acquired JAK2 Mutation in Polycythemia VeraJournal of Biological Chemistry, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisPublished by Elsevier ,2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005